28-Mar-2024
Accelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by $0.45M
Seeking Alpha News (Thu, 28-Mar 4:16 PM ET)
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
PRNewswire (Thu, 28-Mar 4:05 PM ET)
Notable earnings after Thursday's close
Seeking Alpha News (Wed, 27-Mar 5:35 PM ET)
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Seeking Alpha News (Sun, 24-Mar 8:01 AM ET)
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
PRNewswire (Thu, 7-Mar 9:30 AM ET)
PRNewswire (Fri, 19-Jan 9:20 AM ET)
Accelerate Diagnostics Announces Launch of Proposed Public Offering
PRNewswire (Tue, 16-Jan 7:45 AM ET)
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
PRNewswire (Sun, 7-Jan 8:00 PM ET)
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Accelerate Diagnostics trades on the NASDAQ stock market under the symbol AXDX.
As of March 28, 2024, AXDX stock price declined to $0.99 with 84,453 million shares trading.
AXDX has a beta of 0.57, meaning it tends to be less sensitive to market movements. AXDX has a correlation of 0.00 to the broad based SPY ETF.
AXDX has a market cap of $21.09 million. This is considered a Sub-Micro Cap stock.
Last quarter Accelerate Diagnostics reported $3 million in Revenue and -$1.18 earnings per share. This fell short of revenue expectation by $-231,000 and missed earnings estimates by -$.11.
In the last 3 years, AXDX stock traded as high as $94.19 and as low as $.83.
The top ETF exchange traded funds that AXDX belongs to (by Net Assets): VTI, VXF.
AXDX has underperformed the market in the last year with a price return of -80.2% while the SPY ETF gained +33.6%. AXDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -76.3% and -8.3%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
AXDX support price is $.94 and resistance is $1.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXDX stock will trade within this expected range on the day.